

MD7009/MD7259 Clinical Presentation & Management in Diabetes: Glycaemic Control, New & Novel Therapies

View Online



Amori, R. E., Lau, J., & Pittas, A. G. (2007). Efficacy and Safety of Incretin Therapy in Type 2 Diabetes. *JAMA*, 298(2). <https://doi.org/10.1001/jama.298.2.194>

Amy Kennedy. (2013). Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis. *PLoS ONE*, 8(3). <https://doi.org/doi:10.1371/journal.pone.0058861>

Anderson, B., Funnell, M., & American Diabetes Association. (2005). *The art of empowerment: stories and strategies for diabetes educators* (2nd ed). American Diabetes Association.

Anthony H. Barnett, Jenny Grice. (2013). *New Mechanisms in Glucose Control*. BMJ Books; 1 edition. <http://ezproxy.lib.le.ac.uk/login?url=http://lib.myilibrary.com?id=478133>

[ARCHIVED CONTENT] Medicines management: Everybody's business : Department of Health - Publications and statistics. (n.d.). http://webarchive.nationalarchives.gov.uk/20080205142458/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_082200

Ashwell, S. G., Amiel, S. A., Bilous, R. W., Dashora, U., Heller, S. R., Hepburn, D. A., Shutler, S. D., Stephens, J. W., & Home, P. D. (2006). Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. *Diabetic Medicine*, 23(3), 285–292. <https://doi.org/10.1111/j.1464-5491.2005.01781.x>

Atkinson, M. A. (2012). The Pathogenesis and Natural History of Type 1 Diabetes. *Cold Spring Harbor Perspectives in Medicine*, 2(11), a007641–a007641. <https://doi.org/10.1101/cshperspect.a007641>

Avery, L., Flynn, D., van Wersch, A., Sniehotta, F. F., & Trenell, M. I. (2012). Changing Physical Activity Behavior in Type 2 Diabetes: A systematic review and meta-analysis of behavioral interventions. *Diabetes Care*, 35(12), 2681–2689. <https://doi.org/10.2337/dc11-2452>

Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010). Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. *The Lancet*, 375(9733), 2223–2233. [https://doi.org/10.1016/S0140-6736\(10\)60407-2](https://doi.org/10.1016/S0140-6736(10)60407-2)

Barry, V. W., Baruth, M., Beets, M. W., Durstine, J. L., Liu, J., & Blair, S. N. (2014). Fitness vs.

Fatness on All-Cause Mortality: A Meta-Analysis. *Progress in Cardiovascular Diseases*, 56 (4), 382–390. <https://doi.org/10.1016/j.pcad.2013.09.002>

Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., Nicholson, W. K., Hutfless, S., Bass, E. B., & Bolen, S. (2011). Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations. *Annals of Internal Medicine*, 154(9). <https://doi.org/10.7326/0003-4819-154-9-201105030-00336>

Bethel, M. A., Engel, S. S., Green, J. B., Huang, Z., Josse, R. G., Kaufman, K. D., Standl, E., Suryawanshi, S., Van de Werf, F., McGuire, D. K., Peterson, E. D., & Holman, R. R. (2017). Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS). *Diabetes Care*. <https://doi.org/10.2337/dc16-1135>

Beverly M Shields. (2015). Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. *BMJ Open*, 5(11). <https://doi.org/doi:10.1136/bmjopen-2015-009088>

Birkeland, K. I. (2015). Hyperglycaemia in pregnancy: still a lot to learn. *The Lancet Diabetes & Endocrinology*, 3(10), 752–753. [https://doi.org/10.1016/S2213-8587\(15\)00282-X](https://doi.org/10.1016/S2213-8587(15)00282-X)

Bretzel, R. G., Nuber, U., Landgraf, W., Owens, D. R., Bradley, C., & Linn, T. (2008). Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. *The Lancet*, 371(9618), 1073–1084. [https://doi.org/10.1016/S0140-6736\(08\)60485-7](https://doi.org/10.1016/S0140-6736(08)60485-7)

Brown, J., Alwan, N. A., West, J., Brown, S., McKinlay, C. J., Farrar, D., & Crowther, C. A. (1996). Lifestyle interventions for the treatment of women with gestational diabetes. In *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd. <https://doi.org/10.1002/14651858.CD011970.pub2>

Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011). Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes. *Annals of Internal Medicine*, 154(2). <https://doi.org/10.7326/0003-4819-154-2-201101180-00300>

Buse, J. B., Drucker, D. J., Taylor, K. L., Kim, T., Walsh, B., Hu, H., Wilhelm, K., Trautmann, M., Shen, L. Z., & Porter, L. E. (2010). DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. *Diabetes Care*, 33(6), 1255–1261. <https://doi.org/10.2337/dc09-1914>

Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009). Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). *The Lancet*, 374(9683), 39–47. [https://doi.org/10.1016/S0140-6736\(09\)60659-0](https://doi.org/10.1016/S0140-6736(09)60659-0)

Capehorn, M., Polonsky, W. H., Edelman, S., Belton, A., Down, S., Gamerman, V., Nagel, F., Lee, J., & Alzaid, A. (2017). Challenges faced by physicians when discussing the Type 2

- diabetes diagnosis with patients: insights from a cross-national study (IntroDia). *Diabetic Medicine*. <https://doi.org/10.1111/dme.13357>
- Carver, C. (2006). Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes. *The Diabetes Educator*, 32(6), 910–917. <https://doi.org/10.1177/0145721706294259>
- Celia G. Walker. (2015). Modelling the Interplay between Lifestyle Factors and Genetic Predisposition on Markers of Type 2 Diabetes Mellitus Risk. *PLoS ONE*, 10(7). <https://doi.org/doi:10.1371/journal.pone.0131681>
- Chatterjee, S., & Davies, M. (2015). Type 2 diabetes: recent advances in diagnosis and management. *Prescriber*, 26(10), 15–21. <https://doi.org/10.1002/psb.1355>
- Chimen, M., Kennedy, A., Nirantharakumar, K., Pang, T. T., Andrews, R., & Narendran, P. (2012). What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. *Diabetologia*, 55(3), 542–551. <https://doi.org/10.1007/s00125-011-2403-2>
- Choudhary, P., Parrott, N. R., Birtles, L., & Rutter, M. K. (2012). Islet cell transplantation: current status in the UK (2012). *Practical Diabetes*, 29(7), 280–285. <https://doi.org/10.1002/pdi.1707>
- Copeland, K. C., Silverstein, J., Moore, K. R., Prazar, G. E., Raymer, T., Shiffman, R. N., Springer, S. C., Thaker, V. V., Anderson, M., Spann, S. J., & Flinn, S. K. (2013). Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents. *PEDIATRICS*, 131(2), 364–382. <https://doi.org/10.1542/peds.2012-3494>
- Courtney, H., Nayar, R., Rajeswaran, C., & Jandhyala, R. (2017). Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, Volume 10, 79–87. <https://doi.org/10.2147/DMSO.S126763>
- Crasto, W., Jarvis, J., & Davies, M. J. (2016a). Handbook of insulin therapies. Adis. http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745
- Crasto, W., Jarvis, J., & Davies, M. J. (2016b). Handbook of insulin therapies. Adis. http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745
- Crasto, W., Jarvis, J., & Davies, M. J. (2016c). Handbook of insulin therapies. Adis. http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745
- Crasto, W., Jarvis, J., & Davies, M. J. (2016d). Handbook of insulin therapies. Adis. http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745
- Crasto, W., Jarvis, J., & Davies, M. J. (2016e). Handbook of insulin therapies. Adis. http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745

- Crasto, W., Jarvis, J., & Davies, M. J. (2016f). Handbook of insulin therapies. Adis. http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745
- Daly, H., Davies, M., Barnett, J., Amin, S., Gray, G., Leonard, J., Northern, A., Crasto, W., Khunti, K., & Jarvis, J. (2015). Development of a self-management education module for those with type 2 diabetes on injectable therapies. *Practical Diabetes*, 32(8), 305–310a. <https://doi.org/10.1002/pdi.1979>
- Davies, M., Dahl, D., Heise, T., Kiljanski, J., & Mathieu, C. (2017). Introduction of biosimilar insulins in Europe. *Diabetic Medicine*, 34(10), 1340–1353. <https://doi.org/10.1111/dme.13400>
- Davies, M. J., & Chatterjee, S. (2017). Trial watch: Insulin initiation for type 2 diabetes mellitus in primary care. *Nature Reviews Endocrinology*, 13(6), 317–318. <https://doi.org/10.1038/nrendo.2017.41>
- Davies, M. J., Heller, S., Skinner, T. C., Campbell, M. J., Carey, M. E., Craddock, S., Dallosso, H. M., Daly, H., Doherty, Y., Eaton, S., Fox, C., Oliver, L., Rantell, K., Rayman, G., & Khunti, K. (2008). Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. *BMJ*, 336(7642), 491–495. <https://doi.org/10.1136/bmj.39474.922025.BE>
- Davies, M., Storms, F., Shutler, S., Bianchi-Biscay, M., & Gomis, R. (2005). Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine. *Diabetes Care*, 28(6), 1282–1288. <https://doi.org/10.2337/diacare.28.6.1282>
- Deacon, C. F., & Lebovitz, H. E. (2016). Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. *Diabetes, Obesity and Metabolism*, 18(4), 333–347. <https://doi.org/10.1111/dom.12610>
- Dhatariya, K. K., Skedgel, C., & Fordham, R. (2017). The cost of treating diabetic ketoacidosis in the UK: a national survey of hospital resource use. *Diabetic Medicine*, 34(10), 1361–1366. <https://doi.org/10.1111/dme.13427>
- Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010a). Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. *The Lancet*, 375(9733), 2234–2243. [https://doi.org/10.1016/S0140-6736\(10\)60406-0](https://doi.org/10.1016/S0140-6736(10)60406-0)
- Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010b). Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. *The Lancet*, 375(9733), 2234–2243. [https://doi.org/10.1016/S0140-6736\(10\)60406-0](https://doi.org/10.1016/S0140-6736(10)60406-0)
- Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrback, J. L. (2014). Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. *The Lancet*, 384(9951), 1349–1357.

[https://doi.org/10.1016/S0140-6736\(14\)60976-4](https://doi.org/10.1016/S0140-6736(14)60976-4)

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials-
ClinicalKey. (n.d.).

<https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858717301043?returnurl=null&referrer=null>

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. (2016). *New England Journal of Medicine*, 375(18), 1799–1802. <https://doi.org/10.1056/NEJMc1611290>

Evans, M., Schumm-Draeger, P. M., Vora, J., & King, A. B. (2011). A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. *Diabetes, Obesity and Metabolism*, 13(8), 677–684. <https://doi.org/10.1111/j.1463-1326.2011.01395.x>

Frandsen, C. S. S., & Madsbad, S. (2014). Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review. *Diabetic Medicine*, 31(11), 1293–1300. <https://doi.org/10.1111/dme.12561>

Funnell, M. M. (2007). Overcoming Barriers to the Initiation of Insulin Therapy. *Clinical Diabetes*, 25(1), 36–38. <https://doi.org/10.2337/diaclin.25.1.36>

Gallwitz, B., Rosenstock, J., Rauch, T., Bhattacharya, S., Patel, S., von Eynatten, M., Dugi, K. A., & Woerle, H.-J. (2012). 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. *The Lancet*, 380(9840), 475–483. [https://doi.org/10.1016/S0140-6736\(12\)60691-6](https://doi.org/10.1016/S0140-6736(12)60691-6)

Garber, A. J., King, A. B., Prato, S. D., Sreenan, S., Balci, M. K., Muñoz-Torres, M., Rosenstock, J., Endahl, L. A., Francisco, A. M. O., & Hollander, P. (2012). Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. *The Lancet*, 379(9825), 1498–1507. [https://doi.org/10.1016/S0140-6736\(12\)60205-0](https://doi.org/10.1016/S0140-6736(12)60205-0)

Garber, A. J., Ligthelm, R., Christiansen, J. S., & Liebl, A. (2007). Premixed insulin treatment for type 2 diabetes: analogue or human? *Diabetes, Obesity and Metabolism*, 9(5), 630–639. <https://doi.org/10.1111/j.1463-1326.2006.00654.x>

Garber, A. J., Wahlen, J., Wahl, T., Bressler, P., Braceras, R., Allen, E., & Jain, R. (2006). Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). *Diabetes, Obesity and Metabolism*, 8(1), 58–66. <https://doi.org/10.1111/j.1463-1326.2005.00563.x>

Gough, S. C. L. (2007). A review of human and analogue insulin trials. *Diabetes Research and Clinical Practice*, 77(1), 1–15. <https://doi.org/10.1016/j.diabres.2006.10.015>

Gough, S. C. L., Harris, S., Woo, V., & Davies, M. (2013). Insulin degludec: overview of a novel ultra long-acting basal insulin. *Diabetes, Obesity and Metabolism*, 15(4), 301–309. <https://doi.org/10.1111/dom.12052>

- Grammes, J., Stock, W., Mann, C. G., Flynn, E. M., & Kubiak, T. (2017). Focus group study to identify the central facets of fear of hypoglycaemia in people with Type 2 diabetes mellitus. *Diabetic Medicine*. <https://doi.org/10.1111/dme.13506>
- Gray, L. J., Khunti, K., Edwardson, C., Goldby, S., Henson, J., Morris, D. H., Sheppard, D., Webb, D., Williams, S., Yates, T., & Davies, M. J. (2012). Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance. *Diabetologia*, 55(12), 3238–3244. <https://doi.org/10.1007/s00125-012-2725-8>
- Gray, L. J., Khunti, K., Wilmot, E. G., Yates, T., & Davies, M. J. (2014). External validation of two diabetes risk scores in a young UK South Asian population. *Diabetes Research and Clinical Practice*, 104(3), 451–458. <https://doi.org/10.1016/j.diabres.2014.03.018>
- Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., Lachin, J. M., McGuire, D. K., Pencina, M. J., Standl, E., Stein, P. P., Suryawanshi, S., Van de Werf, F., Peterson, E. D., & Holman, R. R. (2015). Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*, 373(3), 232–242. <https://doi.org/10.1056/NEJMoa1501352>
- Gururaj Setty, S., Crasto, W., Jarvis, J., Khunti, K., & Davies, M. J. (2016a). New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. *Postgraduate Medical Journal*, 92(1085), 152–164. <https://doi.org/10.1136/postgradmedj-2015-133716>
- Gururaj Setty, S., Crasto, W., Jarvis, J., Khunti, K., & Davies, M. J. (2016b). New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. *Postgraduate Medical Journal*, 92(1085), 152–164. <https://doi.org/10.1136/postgradmedj-2015-133716>
- Hadjiconstantinou, M., Byrne, J., Bodicoat, D. H., Robertson, N., Eborall, H., Khunti, K., & Davies, M. J. (2016). Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis. *Journal of Medical Internet Research*, 18(10). <https://doi.org/10.2196/jmir.5991>
- Hartman, Y. A. W., Jansen, H. J., Hopman, M. T. E., Tack, C. J., & Thijssen, D. H. J. (2017). Insulin-Associated Weight Gain in Type 2 Diabetes Is Associated With Increases in Sedentary Behavior. *Diabetes Care*, 40(9), e120–e121. <https://doi.org/10.2337/dc17-0787>
- Heinonen, I., Helajärvi, H., Pahkala, K., Heinonen, O. J., Hirvensalo, M., Pälve, K., Tammelin, T., Yang, X., Juonala, M., Mikkilä, V., Kähönen, M., Lehtimäki, T., Viikari, J., & Raitakari, O. T. (2013). Sedentary behaviours and obesity in adults: the Cardiovascular Risk in Young Finns Study. *BMJ Open*, 3(6). <https://doi.org/10.1136/bmjopen-2013-002901>
- Heller, S. R., Colagiuri, S., Vaaler, S., Wolffenbuttel, B. H. R., Koelendorf, K., Friberg, H. H., Windfeld, K., & Lindholm, A. (2004). Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes. *Diabetic Medicine*, 21(7), 769–775. <https://doi.org/10.1111/j.1464-5491.2004.01244.x>
- Henson, Joseph. (2014). Associations of Sedentary Time with Fat Distribution in a High-Risk

Population. <https://ira.le.ac.uk/handle/2381/32505>

Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., & Home, P. (2006). A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes. *Diabetes Care*, 29(6), 1269–1274. <https://doi.org/10.2337/dc05-1365>

Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007). Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. *New England Journal of Medicine*, 357(17), 1716–1730. <https://doi.org/10.1056/NEJMoa075392>

Holman, R. R., & Turner, R. C. (1985). A Practical Guide to Basal and Prandial Insulin Therapy. *Diabetic Medicine*, 2(1), 45–53. <https://doi.org/10.1111/j.1464-5491.1985.tb00592.x>

Home, P. D. (2012). The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. *Diabetes, Obesity and Metabolism*, 14(9), 780–788. <https://doi.org/10.1111/j.1463-1326.2012.01580.x>

Horvath, K., Jeitler, K., Berghold, A., Ebrahim, S. H., Gratzner, T. W., Plank, J., Kaiser, T., Pieber, T. R., & Siebenhofer, A. (1996a). Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. In *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd. <https://doi.org/10.1002/14651858.CD005613.pub3>

Horvath, K., Jeitler, K., Berghold, A., Ebrahim, S. H., Gratzner, T. W., Plank, J., Kaiser, T., Pieber, T. R., & Siebenhofer, A. (1996b). Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. In *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd. <https://doi.org/10.1002/14651858.CD005613.pub3>

Htike, Z. Z., Zaccardi, F., Chatterjee, S., Khunti, K., & Davies, M. J. (2016). Glucagon like peptide-1 receptor agonist (GLP-1RA) therapy in management of type 2 diabetes: choosing the right agent for individualised care. *British Journal of Diabetes*, 16(3). <https://doi.org/10.15277/bjd.2016.091>

Htike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2017a). Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. *Diabetes, Obesity and Metabolism*, 19(4), 524–536. <https://doi.org/10.1111/dom.12849>

Htike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2017b). Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. *Diabetes, Obesity and Metabolism*, 19(4), 524–536. <https://doi.org/10.1111/dom.12849>

Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015). Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*, 38(1), 140–149. <https://doi.org/10.2337/dc14-2441>

- Ismail-Beigi, F. (2012). Glycemic Management of Type 2 Diabetes Mellitus. *New England Journal of Medicine*, 366(14), 1319–1327. <https://doi.org/10.1056/NEJMcp1013127>
- John M Jakicic. (2005). Physical activity considerations for the treatment and prevention of obesity. *The American Journal of Clinical Nutrition*, 82(1), 226S-229S. <http://ajcn.nutrition.org/content/82/1/226S>
- Johnston, B. C., Kanters, S., Bandayrel, K., Wu, P., Naji, F., Siemieniuk, R. A., Ball, G. D. C., Busse, J. W., Thorlund, K., Guyatt, G., Jansen, J. P., & Mills, E. J. (2014). Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults. *JAMA*, 312(9). <https://doi.org/10.1001/jama.2014.10397>
- Jones, A. G., & Hattersley, A. T. (2013). The clinical utility of C-peptide measurement in the care of patients with diabetes. *Diabetic Medicine*, 30(7), 803–817. <https://doi.org/10.1111/dme.12159>
- Kamlesh Khunti. (2015). Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes. *PLoS ONE*, 10(9). <https://doi.org/doi:10.1371/journal.pone.0135702>
- Kenneth Hodson. (2010). Gestational diabetes: emerging concepts in pathophysiology. *Obstetric Medicine*, 3(4). <https://doi.org/doi:10.1258/om.2010.100025>
- Latika Sahu. (2009). Comparison of the American Diabetes Association and World Health Organization criteria for gestational diabetes mellitus and the outcomes of pregnancy. *Obstetric Medicine*, 2(4). <https://doi.org/doi:10.1258/om.2009.080049>
- Lee, I.-M. (2010). Physical Activity and Weight Gain Prevention. *JAMA*, 303(12). <https://doi.org/10.1001/jama.2010.312>
- Leff, D. R., & Heath, D. (2009). Surgery for obesity in adulthood. *BMJ*, 339(sep22 1), b3402–b3402. <https://doi.org/10.1136/bmj.b3402>
- Levin, P. A., Nguyen, H., Wittbrodt, E., & Kim, S. C. (2017). Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, Volume 10, 123–139. <https://doi.org/10.2147/DMSO.S130834>
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. (2016). *New England Journal of Medicine*, 375(18), 1797–1799. <https://doi.org/10.1056/NEJMc1611289>
- Mäkimattila, S., Nikkilä, K., & Yki-Järvinen, H. (1999). Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. *Diabetologia*, 42(4), 406–412. <https://doi.org/10.1007/s001250051172>
- Marre, M., Shaw, J., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., & Colagiuri, S. (2009). Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). *Diabetic Medicine*, 26(3), 268–278. <https://doi.org/10.1111/j.1464-5491.2009.02666.x>

Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Woo, V., Hansen, O., Holst, A. G., Pettersson, J., & Vilsbøll, T. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine*, 375(19), 1834–1844.
<https://doi.org/10.1056/NEJMoa1607141>

Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., Steinberg, W. M., Stockner, M., Zinman, B., Bergenstal, R. M., & Buse, J. B. (2016a). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*, 375(4), 311–322.
<https://doi.org/10.1056/NEJMoa1603827>

Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., Steinberg, W. M., Stockner, M., Zinman, B., Bergenstal, R. M., & Buse, J. B. (2016b). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*, 375(4), 311–322.
<https://doi.org/10.1056/NEJMoa1603827>

Merlin C. Thomas. (2016). Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. *Diabetes Therapy*, 7(3).
<https://doi.org/doi:10.1007/s13300-016-0189-4>

Michael Riddell. (2009). Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the Role for Continuous Glucose Monitoring. *Journal of Diabetes Science and Technology (Online)*, 3(4). <https://doi.org/doi:10.1177/193229680900300439>

Min, S. H., Yoon, J.-H., Hahn, S., & Cho, Y. M. (2017). Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. *Diabetes/Metabolism Research and Reviews*, 33(1).
<https://doi.org/10.1002/dmrr.2818>

Minimizing Hypoglycemia in Diabetes: Table 1. (2015). *Diabetes Care*, 38(8), 1583–1591.
<https://doi.org/10.2337/dc15-0279>

Mishriky, B. M., Cummings, D. M., & Tanenberg, R. J. (2015a). The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. *Diabetes Research and Clinical Practice*, 109(2), 378–388. <https://doi.org/10.1016/j.diabres.2015.05.025>

Mishriky, B. M., Cummings, D. M., & Tanenberg, R. J. (2015b). The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. *Diabetes Research and Clinical Practice*, 109(2), 378–388. <https://doi.org/10.1016/j.diabres.2015.05.025>

Moreno-Castilla, C., Mauricio, D., & Hernandez, M. (2016). Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus. *Current Diabetes Reports*, 16(4). <https://doi.org/10.1007/s11892-016-0717-7>

Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006). Management of Hyperglycemia in Type 2 Diabetes: A Consensus

Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*, 29(8), 1963–1972. <https://doi.org/10.2337/dc06-9912>

Nauck, M. (2016). Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. *Diabetes, Obesity and Metabolism*, 18(3), 203–216. <https://doi.org/10.1111/dom.12591>

Nauck, M. A., & Meier, J. J. (2016). The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. *The Lancet Diabetes & Endocrinology*, 4(6), 525–536. [https://doi.org/10.1016/S2213-8587\(15\)00482-9](https://doi.org/10.1016/S2213-8587(15)00482-9)

Nauck, M. A., Meininger, G., Sheng, D., Terranella, L., & Stein, P. P. (2007). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. *Diabetes, Obesity and Metabolism*, 9(2), 194–205. <https://doi.org/10.1111/j.1463-1326.2006.00704.x>

Nauck, M., Weinstock, R. S., Umpierrez, G. E., Guerci, B., Skrivanek, Z., & Milicevic, Z. (2014). Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). *Diabetes Care*, 37(8), 2149–2158. <https://doi.org/10.2337/dc13-2761>

Nissen, S. E., & Wolski, K. (2007). Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. *New England Journal of Medicine*, 356(24), 2457–2471. <https://doi.org/10.1056/NEJMoa072761>

Nolan, C. J., Ruderman, N. B., Kahn, S. E., Pedersen, O., & Prentki, M. (2015). Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. *Diabetes*, 64(3), 673–686. <https://doi.org/10.2337/db14-0694>

Paul Craddy. (2014). Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison. *Diabetes Therapy*, 5(1). <https://doi.org/doi:10.1007/s13300-014-0061-3>

Persaud, S. J., & Jones, P. M. (2016). A Wake-up Call for Type 2 Diabetes? *New England Journal of Medicine*, 375(11), 1090–1092. <https://doi.org/10.1056/NEJMcibr1607950>

Postnatal testing following gestational diabetes- ClinicalKey. (n.d.). <https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858715003228?returnurl=null&referrer=null>

Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes. (4 C.E.). <https://www.youtube.com/watch?v=AhhWTmEFuag>

Qin, L., Knol, M. J., Corpeleijn, E., & Stolck, R. P. (2010). Does physical activity modify the risk of obesity for type 2 diabetes: a review of epidemiological data. *European Journal of Epidemiology*, 25(1), 5–12. <https://doi.org/10.1007/s10654-009-9395-y>

Raskin, P., Allen, E., Hollander, P., Lewin, A., Gabbay, R. A., Hu, P., Bode, B., & Garber, A. (2005). Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs. *Diabetes Care*, 28(2), 260–265. <https://doi.org/10.2337/diacare.28.2.260>

Resources and tools. (n.d.-a).

<http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/78:global-guideline-for-managing-older-people-with-type-2-diabetes.html>

Resources and tools. (n.d.-b).

<http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/79:global-guideline-for-type-2-diabetes.html>

Resources and tools. (n.d.-c).

<http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/80:the-global-idf-ispad-guidelines-for-diabetes-in-childhood-and-adolescence.html>

Richard I. G. Holt, , Clive Cockram, , Allan Flyvbjerg, , and Barry J. Goldstein. (2016). *Textbook of Diabetes*. John Wiley.

<https://ebookcentral-proquest-com.ezproxy4.lib.le.ac.uk/lib/leicester/reader.action?docID=4769056>

Richter, B., & Neises, G. (1996). 'Human' insulin versus animal insulin in people with diabetes mellitus. In *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd. <https://doi.org/10.1002/14651858.CD003816.pub2>

Riddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013). Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). *Diabetes Care*, 36(9), 2489–2496. <https://doi.org/10.2337/dc12-2454>

Rinki Murphy. (2015). Monogenic diabetes and pregnancy. *Obstetric Medicine*, 8(3). <https://doi.org/doi:10.1177/1753495X15590713>

Rizos, C. V., Kei, A., & Elisaf, M. S. (2016). The current role of thiazolidinediones in diabetes management. *Archives of Toxicology*, 90(8), 1861–1881. <https://doi.org/10.1007/s00204-016-1737-4>

Rosenstock, J., Davies, M., Home, P. D., Larsen, J., Koenen, C., & Schernthaner, G. (2008). A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetes. *Diabetologia*, 51(3), 408–416. <https://doi.org/10.1007/s00125-007-0911-x>

Rosenstock, J., Raccah, D., Koranyi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013). Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X). *Diabetes Care*, 36(10), 2945–2951. <https://doi.org/10.2337/dc12-2709>

Rotz, M. E., Ganetsky, V. S., Sen, S., & Thomas, T. F. (2015). Implications of incretin-based therapies on cardiovascular disease. *International Journal of Clinical Practice*, 69(5),

531–549. <https://doi.org/10.1111/ijcp.12572>

Ryder, B., McKnight, J., Blann, A., Dhatariya, K., Gregory, R., Robinson, T., Rowles, S., Sharp, P., Winocour, P. H., & Walton, C. (2013). ABCD position statement on GLP-1 based therapies and pancreatic damage. *Practical Diabetes*, 30(9), 388–391. <https://doi.org/10.1002/pdi.1816>

S M Attard. (2015). Implications of iron deficiency/anemia on the classification of diabetes using HbA1c. *Nutrition & Diabetes*, 5(6). <https://doi.org/doi:10.1038/nutd.2015.16>

Safety and insulin: Implementation of national guidance at a local level | Journal Content | Diabetesonthenet.com. (n.d.). <http://www.diabetesonthenet.com/journal-content/view/safety-and-insulin-implementation-of-national-guidance-at-a-local-level>

Sallis, J. F., Bull, F., Guthold, R., Heath, G. W., Inoue, S., Kelly, P., Oyeyemi, A. L., Perez, L. G., Richards, J., & Hallal, P. C. (2016). Progress in physical activity over the Olympic quadrennium. *The Lancet*, 388(10051), 1325–1336. [https://doi.org/10.1016/S0140-6736\(16\)30581-5](https://doi.org/10.1016/S0140-6736(16)30581-5)

Samuel, V. T., & Shulman, G. I. (2012). Intergrating Mechanisms for Insulin Resistance: Common Threads and Missing Links. *Cell*, 148(5), 852–871. <https://doi.org/10.1016/j.cell.2012.02.017>

Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., & Kashyap, S. R. (2017). Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. *New England Journal of Medicine*, 376(7), 641–651. <https://doi.org/10.1056/NEJMoa1600869>

Schauer, P. R., Kashyap, S. R., Wolski, K., Brethauer, S. A., Kirwan, J. P., Pothier, C. E., Thomas, S., Abood, B., Nissen, S. E., & Bhatt, D. L. (2012a). Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. *New England Journal of Medicine*, 366(17), 1567–1576. <https://doi.org/10.1056/NEJMoa1200225>

Schauer, P. R., Kashyap, S. R., Wolski, K., Brethauer, S. A., Kirwan, J. P., Pothier, C. E., Thomas, S., Abood, B., Nissen, S. E., & Bhatt, D. L. (2012b). Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. *New England Journal of Medicine*, 366(17), 1567–1576. <https://doi.org/10.1056/NEJMoa1200225>

Schwartz, S. S., Epstein, S., Corkey, B. E., Grant, S. F. A., Gavin, J. R., & Aguilar, R. B. (2016). The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β -Cell-Centric Classification Schema. *Diabetes Care*, 39(2), 179–186. <https://doi.org/10.2337/dc15-1585>

Simmons, R. K., Borch-Johnsen, K., Lauritzen, T., Rutten, G. E., Sandbæk, A., van den Donk, M., Black, J. A., Tao, L., Wilson, E. C., Davies, M. J., Khunti, K., Sharp, S. J., Wareham, N. J., & Griffin, S. J. (2016). A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study. *Health Technology Assessment*, 20(64), 1–86. <https://doi.org/10.3310/hta20640>

- Sivasubramaniam, S., Amiel, S. A., & Choudhary, P. (2017). Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range. *Diabetic Medicine*, 34(10), 1456–1460. <https://doi.org/10.1111/dme.13438>
- Sjöström, L., Lindroos, A.-K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjöström, C. D., Sullivan, M., & Wedel, H. (2004). Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery. *New England Journal of Medicine*, 351(26), 2683–2693. <https://doi.org/10.1056/NEJMoa035622>
- Srinivasan, B. T., & Davies, M. (2014). Glycaemic management of type 2 diabetes. *Medicine*, 42(12), 711–717. <https://doi.org/10.1016/j.mpmed.2014.09.011>
- Srinivasan, B. T., Jarvis, J., Khunti, K., & Davies, M. J. (2008). Recent advances in the management of type 2 diabetes mellitus: a review. *Postgraduate Medical Journal*, 84(996), 524–531. <https://doi.org/10.1136/pgmj.2008.067918>
- Srinivasan, P., Huang, G. C., Amiel, S. A., & Heaton, N. D. (2007). Islet cell transplantation. *Postgraduate Medical Journal*, 83(978), 224–229. <https://doi.org/10.1136/pgmj.2006.053447>
- Standards of Medical Care in Diabetes--2015: Summary of Revisions. (2015). *Diabetes Care*, 38(Supplement_1), S4–S4. <https://doi.org/10.2337/dc15-S003>
- Steven, S., Hollingsworth, K. G., Al-Mrabeh, A., Avery, L., Aribisala, B., Caslake, M., & Taylor, R. (2016). Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders. *Diabetes Care*, 39(5), 808–815. <https://doi.org/10.2337/dc15-1942>
- Steven, S., & Taylor, R. (2015). Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes. *Diabetic Medicine*, 32(9), 1149–1155. <https://doi.org/10.1111/dme.12722>
- Stewart, Z. A., Wilinska, M. E., Hartnell, S., Temple, R. C., Rayman, G., Stanley, K. P., Simmons, D., Law, G. R., Scott, E. M., Hovorka, R., & Murphy, H. R. (2016). Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. *New England Journal of Medicine*, 375(7), 644–654. <https://doi.org/10.1056/NEJMoa1602494>
- Swinnen, S. G., Simon, A. C., Holleman, F., Hoekstra, J. B., & DeVries, J. H. (1996). Insulin detemir versus insulin glargine for type 2 diabetes mellitus. In *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd. <https://doi.org/10.1002/14651858.CD006383.pub2>
- Tanner, M. (2016). Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia. *Annals of Internal Medicine*, 165(4). <https://doi.org/10.7326/ACPJC-2016-165-4-020>
- Tao, L., Wilson, E. C. F., Wareham, N. J., Sandbaek, A., Rutten, G. E. H. M., Lauritzen, T., Khunti, K., Davies, M. J., Borch-Johnsen, K., Griffin, S. J., & Simmons, R. K. (2015). Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. *Diabetic Medicine*, 32(7), 907–919.

<https://doi.org/10.1111/dme.12711>

Type 2 diabetes in adults: management | Guidance and guidelines | NICE. (n.d.).
<https://www.nice.org.uk/guidance/ng28>

Umpierre, D. (2011). Physical Activity Advice Only or Structured Exercise Training and Association With HbA_{1c} Levels in Type 2 Diabetes. *JAMA*, 305(17).
<https://doi.org/10.1001/jama.2011.576>

Unit 3 – Special care groups: A practical guide to pregnancy complicated by diabetes - Diabetes & Primary Care. (n.d.).
<http://www.diabetesandprimarycare.co.uk/journal-content/view/unit-3-special-care-groups-a-practical-guide-to-pregnancy-complicated-by-diabetes/?preview>

Villani, M., de Courten, B., & Zoungas, S. (2017). Emergency treatment of hypoglycaemia: a guideline and evidence review. *Diabetic Medicine*, 34(9), 1205–1211.
<https://doi.org/10.1111/dme.13379>

Vloemans, A. F., van Beers, C. A. J., de Wit, M., Cleijne, W., Rondags, S. M., Geelhoed-Duijvestijn, P. H., Kramer, M. H. H., Serné, E. H., & Snoek, F. J. (2017). Keeping safe. Continuous glucose monitoring (CGM) in persons with Type 1 diabetes and impaired awareness of hypoglycaemia: a qualitative study. *Diabetic Medicine*, 34(10), 1470–1476.
<https://doi.org/10.1111/dme.13429>

Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016). Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *New England Journal of Medicine*, 375(4), 323–334. <https://doi.org/10.1056/NEJMoa1515920>

WHO 2011 Use of glycated haemoglobin (HbA_{1c}) in the diagnosis of diabetes mellitus. (n.d.). http://www.who.int/diabetes/publications/diagnosis_diabetes2011/en/

Yeh, J. S., Kushner, R. F., & Schiff, G. D. (2016). Obesity and Management of Weight Loss. *New England Journal of Medicine*, 375(12), 1187–1189.
<https://doi.org/10.1056/NEJMclde1515935>

Yki-Järvinen, H., Kauppinen-Mäkelin, R., Tiikkainen, M., Vähätalo, M., Virtamo, H., Nikkilä, K., Tulokas, T., Hulme, S., Hardy, K., McNulty, S., Hänninen, J., Levänen, H., Lahdenperä, S., Lehtonen, R., & Ryysy, L. (2006). Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. *Diabetologia*, 49(3), 442–451.
<https://doi.org/10.1007/s00125-005-0132-0>

Young, L. A., & Buse, J. B. (2014). GLP-1 receptor agonists and basal insulin in type 2 diabetes. *The Lancet*, 384(9961), 2180–2181.
[https://doi.org/10.1016/S0140-6736\(14\)61409-4](https://doi.org/10.1016/S0140-6736(14)61409-4)

Young-Hyman, D., de Groot, M., Hill-Briggs, F., Gonzalez, J. S., Hood, K., & Peyrot, M. (2017). Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. *Diabetes Care* 2016;39:2126–2140. *Diabetes Care*, 40(2), 287.1–287. <https://doi.org/10.2337/dc17-er02>

Zaccardi, F., Webb, D. R., Yates, T., & Davies, M. J. (2016). Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. *Postgraduate Medical Journal*, 92(1084), 63–69. <https://doi.org/10.1136/postgradmedj-2015-133281>

Zinman, B., Fulcher, G., Rao, P. V., Thomas, N., Endahl, L. A., Johansen, T., Lindh, R., Lewin, A., Rosenstock, J., Pinget, M., & Mathieu, C. (2011). Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. *The Lancet*, 377(9769), 924–931. [https://doi.org/10.1016/S0140-6736\(10\)62305-7](https://doi.org/10.1016/S0140-6736(10)62305-7)